Search Results - "PARISER, David"

Building a Group Practice and Going Big by Pariser, David M.

“…Guided by experiences learned over 50 years of guiding a solo practice to an independent private practice with 28 providers and 7 practice locations in…”
Get full text

Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies by Elewski, Boni E., MD, Rich, Phoebe, MD, Pollak, Richard, DPM, Pariser, David M., MD, Watanabe, Shinichi, MD, Senda, Hisato, DVM, Ieda, Chikara, PharB, Smith, Kathleen, MBA, Pillai, Radhakrishnan, PhD, Ramakrishna, Tage, MD, Olin, Jason T., PhD

“…Background Onychomycosis is a common nail infection, often resulting in nail plate damage and deformity. Topical lacquer treatments have negligible efficacy…”
Get full text

Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial by Pariser, David M., Bagel, Jerry, Lebwohl, Mark, Yosipovitch, Gil, Chien, Elaine, Spellman, Mary C.

“…Pruritus, a common symptom of psoriasis, negatively affects quality of life; however, treatment of lesional skin does not consistently alleviate psoriatic…”
Get full text

Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT) by Pariser, David M., Simpson, Eric L., Gadkari, Abhijit, Bieber, Thomas, Margolis, David J., Brown, Michelle, Nelson, Lauren, Mahajan, Puneet, Reaney, Matthew, Guillemin, Isabelle, Mallya, Usha G., Eckert, Laurent

“…Objectives: The Atopic Dermatitis Control Tool (ADCT) was designed to evaluate patient-perceived AD control and facilitate patient-physician discussion on…”
Get full text

Open-Label Cohort Study to Evaluate Efficacy and Safety of Application of Glycopyrronium Cloth, 2.4% for Palmar Hyperhidrosis by Pariser, David, Rivera, Erin, Benedict, Danielle

“…Hyperhidrosis of the palms has a significant negative impact on quality of life. There is no FDA-approved treatment; however, clinicians often use…”
Get more information

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis by Armstrong, April W., MD, MPH, Siegel, Michael P., PhD, Bagel, Jerry, MD, Boh, Erin E., MD, PhD, Buell, Megan, Cooper, Kevin D., MD, Callis Duffin, Kristina, MD, MS, Eichenfield, Lawrence F., MD, Garg, Amit, MD, Gelfand, Joel M., MD, MSCE, Gottlieb, Alice B., MD, PhD, Koo, John Y.M., MD, Korman, Neil J., MD, PhD, Krueger, Gerald G., MD, Lebwohl, Mark G., MD, Leonardi, Craig L., MD, Mandelin, Arthur M., MD, PhD, Menter, M. Alan, MD, Merola, Joseph F., MD, MMSC, Pariser, David M., MD, Prussick, Ronald B., MD, FRCP, Ryan, Caitriona, MD, Shah, Kara N., MD, Weinberg, Jeffrey M., MD, Williams, MaryJane O.U., MD, Wu, Jashin J., MD, Yamauchi, Paul S., MD, PhD, Van Voorhees, Abby S., MD

“…Background An urgent need exists in the United States to establish treatment goals in psoriasis. Objective We aim to establish defined treatment targets toward…”
Get full text

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial by Blauvelt, Andrew, Dr, de Bruin-Weller, Marjolein, MD, Gooderham, Melinda, MD, Cather, Jennifer C, MD, Weisman, Jamie, MD, Pariser, David, Prof, Simpson, Eric L, Prof, Papp, Kim A, MD, Hong, H Chih-Ho, MD, Rubel, Diana, MD, Foley, Peter, MD, Prens, Errol, Prof, Griffiths, Christopher E M, Prof, Etoh, Takafumi, MD, Pinto, Pedro Herranz, MD, Pujol, Ramon M, MD, Szepietowski, Jacek C, Prof, Ettler, Karel, MD, Kemény, Lajos, Prof, Zhu, Xiaoping, PhD, Akinlade, Bolanle, MD, Hultsch, Thomas, MD, Mastey, Vera, MS, Gadkari, Abhijit, PhD, Eckert, Laurent, PhD, Amin, Nikhil, MD, Graham, Neil M H, MD, Pirozzi, Gianluca, MD, Stahl, Neil, PhD, Yancopoulos, George D, MD, Shumel, Brad, MD

“…Summary Background Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines…”
Get full text

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial by Forman, Seth B., Pariser, David M., Poulin, Yves, Vincent, Michael S., Gilbert, Steven A., Kieras, Elizabeth M., Qiu, Ruolun, Yu, Dahong, Papacharalambous, Jocelyne, Tehlirian, Christopher, Peeva, Elena

“…We report results from a phase IIa study of efficacy and safety of PF-06700841, an oral TYK2/Jak1 inhibitor, in patients with moderate-to-severe plaque…”
Get full text

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis by Bissonnette, Robert, MD, Pariser, David M., MD, Wasel, Norman R., MD, FRCPC, Goncalves, Joana, MD, Day, Robert M., PhD, Chen, Rongdean, PhD, Sebastian, Michael, MD

“…Background Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality of life. Objective We evaluated the efficacy and…”
Get full text

A Pivotal Study on the Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating by Smith, Stacy, Glaser, Dee Anna, Green, Lawerence J, Kaminer, Micheal S, Tims, Erin, Pariser, David M

“…One-third of US adults are bothered by excessive sweating, approximately 5% are diagnosed with hyperhidrosis. A topical patch using targeted alkali thermolysis…”
Get full text

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis by Paller, Amy S., MD, Siegfried, Elaine C., MD, Pariser, David M., MD, Rice, Kara Creamer, MS, Trivedi, Mona, MD, Iles, Jan, MD, Collier, David H., MD, Kricorian, Greg, MD, Langley, Richard G., MD

“…Background There are no systemic therapies approved in the United States to treat pediatric psoriasis. Objective We sought to evaluate long-term safety and…”
Get full text

Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study by Gupta, Aditya K., Surprenant, Maria S., Kempers, Steven E., Pariser, David M., Rensfeldt, Kjell, Tavakkol, Amir

“…Onychomycosis is a recalcitrant fungal nail infection. Topical antifungal agents may be preferred over systemic agents due to lack of systemic adverse effects…”
Get full text

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials by Glaser, Dee Anna, Hebert, Adelaide A., Nast, Alexander, Werschler, William P., Green, Lawrence, Mamelok, Richard, Drew, Janice, Quiring, John, Pariser, David M.

“…Glycopyrronium tosylate (GT) is a topical anticholinergic developed for once-daily treatment of primary axillary hyperhidrosis. Assess the efficacy and safety…”
Get full text

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials by Gold, Linda Stein, Lebwohl, Mark G., Sugarman, Jeffrey L., Pariser, David M., Lin, Tina, Martin, Gina, Pillai, Radhakrishnan, Israel, Robert, Ramakrishna, Tage

“…Topical corticosteroids are the mainstay of psoriasis treatment, with long-term safety considerations limiting their use. Combining them with tazarotene may…”
Get full text

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials by Lebwohl, Mark G, Kircik, Leon H, Moore, Angela Y, Stein Gold, Linda, Draelos, Zoe D, Gooderham, Melinda J, Papp, Kim A, Bagel, Jerry, Bhatia, Neal, Del Rosso, James Q, Ferris, Laura K, Green, Lawrence J, Hebert, Adelaide A, Jones, Terry, Kempers, Steven E, Pariser, David M, Yamauchi, Paul S, Zirwas, Matthew, Albrecht, Lorne, Devani, Alim R, Lomaga, Mark, Feng, Amy, Snyder, Scott, Burnett, Patrick, Higham, Robert C, Berk, David R

“…IMPORTANCE: Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in a phase 2b trial of…”
Get full text

Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients by Zager, Jonathan S, Gastman, Brian R, Leachman, Sancy, Gonzalez, Rene C, Fleming, Martin D, Ferris, Laura K, Ho, Jonhan, Miller, Alexander R, Cook, Robert W, Covington, Kyle R, Meldi-Plasseraud, Kristen, Middlebrook, Brooke, Kaminester, Lewis H, Greisinger, Anthony, Estrada, Sarah I, Pariser, David M, Cranmer, Lee D, Messina, Jane L, Vetto, John T, Wayne, Jeffrey D, Delman, Keith A, Lawson, David H, Gerami, Pedram

“…The heterogeneous behavior of patients with melanoma makes prognostication challenging. To address this, a gene expression profile (GEP) test to predict…”
Get full text

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial by Thaçi, Diamant, Vender, Ron, de Rie, Menno A, Conrad, Curdin, Pariser, David M, Strober, Bruce, Vanvoorden, Veerle, Wang, Maggie, Madden, Cynthia, de Cuyper, Dirk, Kimball, Alexa B

“…BE SURE 1-year results demonstrated the superior efficacy of bimekizumab compared with adalimumab with no unexpected safety findings. To provide efficacy and…”
Get full text

Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus by Braathen, Lasse R., MD, PhD, MHA, Szeimies, Rolf-Markus, MD, PhD, Basset-Seguin, Nicole, MD, PhD, Bissonnette, Robert, MD, Foley, Peter, MBBS, BMedSc, MD, Pariser, David, MD, Roelandts, Rik, MD, PhD, Wennberg, Ann-Marie, MD, PhD, Morton, Colin A., MBChB, MD, FRCP

“…Topical photodynamic therapy (PDT) is used to treat nonmelanoma skin cancers, such as actinic keratoses, Bowen's disease, and basal cell carcinoma (superficial…”
Get full text

Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis by Pariser, David M., Lain, Edward L., Mamelok, Richard D., Drew, Janice, Mould, Diane R.

“…Background Glycopyrronium tosylate (GT; Qbrexza ® [glycopyrronium] cloth, 2.4%) is a topical anticholinergic approved (USA) for primary axillary hyperhidrosis…”
Get full text

Topical 0.5% Ivermectin Lotion for Treatment of Head Lice by Pariser, David M, Meinking, Terri Lynn, Bell, Margie, Ryan, William G

“…New treatments for head lice are needed. In this pair of randomized, controlled trials involving 765 patients, a single application of topical ivermectin had…”
Get full text